Thus we propose that a combination of tumor morphology, together with cytoplasmic LIN28 immunostaining and C19MC genetic status, is needed to robustly distinguish group 1 CNS-PNETs or related embryonal tumors from other malignant pediatric brain tumors which may exhibit varying LIN28 expression. This evidence concerns the gene LIN28A and brain neoplasm.